{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:02:18Z","timestamp":1771639338366,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"GlaxoSmithKline and Teva Neuroscience"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.parkreldis.2012.01.008","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T12:19:20Z","timestamp":1328876360000},"page":"488-493","source":"Crossref","is-referenced-by-count":48,"title":["Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson\u2019s disease: A prospective, open-label extension study"],"prefix":"10.1016","volume":"18","author":[{"given":"Lawrence W.","family":"Elmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Surmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Boroojerdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.parkreldis.2012.01.008_bib1","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1353-8020(09)70772-2","article-title":"New considerations in the medical management of early Parkinson\u2019s disease: impact of recent clinical trials on treatment strategy","volume":"15","author":"Hauser","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/1531-8257(199907)14:4<605::AID-MDS1009>3.0.CO;2-H","article-title":"Evolution of motor fluctuations in Parkinson\u2019s disease: a longitudinal study over 6 years","volume":"14","author":"Reardon","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.nurt.2007.12.001","article-title":"Current status of symptomatic medical therapy in Parkinson\u2019s disease","volume":"5","author":"Factor","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"Suppl. 11","key":"10.1016\/j.parkreldis.2012.01.008_bib4","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.65.2_suppl_1.S3","article-title":"A\u00a0novel dopamine agonist for the transdermal treatment of Parkinson\u2019s disease","volume":"65","author":"Jenner","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1358\/dot.2010.46.7.1463530","article-title":"Rotigotine transdermal patch for the treatment of Parkinson\u2019s disease and restless legs syndrome","volume":"46","author":"Boroojerdi","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1517\/14656560902746041","article-title":"Rotigotine transdermal delivery for the treatment of Parkinson\u2019s disease","volume":"10","author":"Rascol","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib9","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.21741","article-title":"Rotigotine transdermal patch in early Parkinson\u2019s disease: a randomized, double-blind, controlled study versus placebo and ropinirole","volume":"22","author":"Giladi","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","article-title":"A\u00a0controlled trial of rotigotine monotherapy in early Parkinson\u2019s disease","volume":"60","author":"Parkinson Study Group","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archneur.64.5.676","article-title":"Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease","volume":"64","author":"Jankovic","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","article-title":"Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study","volume":"68","author":"LeWitt","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.clinthera.2008.05.007","article-title":"Rotigotine transdermal system for the treatment of Parkinson\u2019s disease","volume":"30","author":"Pham","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib15","first-page":"S280","article-title":"Changes in early morning motor status following adjunctive treatment of advanced Parkinson\u2019s disease with rotigotine transdermal system in two large, placebo-controlled trials (PREFER and CLEOPATRA-PD)","volume":"24","author":"Pahwa","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: A double-blind, randomized, placebo-controlled study (RECOVER)","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease","volume":"66","author":"Parkinson Study Group","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib18","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.21743","article-title":"Ten-year follow-up of Parkinson\u2019s disease patients randomized to initial therapy with ropinirole or levodopa","volume":"22","author":"Hauser","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib19","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib20","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A\u00a0five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A\u00a0new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson\u2019s disease: results from a European multicenter trial","volume":"20","author":"M\u00f6ller","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1474-4422(09)70225-X","article-title":"A\u00a0reassessment of risks and benefits of dopamine agonists in Parkinson\u2019s disease","volume":"8","author":"Antonini","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.parkreldis.2010.06.003","article-title":"Classifying risk factors for dyskinesia in Parkinson\u2019s disease","volume":"16","author":"Sharma","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl. 7","key":"10.1016\/j.parkreldis.2012.01.008_bib25","first-page":"VII2-6","article-title":"The natural history of Parkinson\u2019s disease","volume":"253","author":"Poewe","year":"2006","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.parkreldis.2012.01.008_bib26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1474-4422(11)70127-2","article-title":"Long-term safety and efficacy of rotigotine transdermal system in moderate to severe idiopathic restless legs syndrome: a 5-year open-label extension study","volume":"10","author":"Oertel","year":"2011","journal-title":"Lancet Neurol"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802012000260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802012000260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T10:25:04Z","timestamp":1543227904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802012000260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1353802012000260"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2012.01.008","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}